Rodriguez Rosemarie, Fadare Oluwole
Department of Pathology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA.
Int J Gynecol Pathol. 2008 Jan;27(1):108-12. doi: 10.1097/pgp.0b013e31804216b8.
The 2001 consensus guidelines essentially equated the follow-up management of patients with a Papanicolaou (Pap) test interpretation of negative for intraepithelial lesion or malignancy and those with an interpretation of atypical squamous cells of undetermined significance (ASC-US) that was followed by a negative reflex test for high-risk human papillomavirus (HR HPV) types: follow-up cytology in 12 months. As several years have elapsed since these guidelines attained some measure of widespread implementation, we sought to determine whether, in routinely diagnosed cases, the full spectrum of follow-up cytological findings are indeed identical in these 2 groups. Clinical and pathological data of consecutive patients with a Pap test interpretation of ASC-US during a 6-week period (n = 587), in which reflex human papillomavirus testing was performed (n = 497) and in which HR HPV types were not detected (n = 300), were reviewed (study group). A randomly selected control group of 300 patients whose Pap tests were reported as negative (negative for intraepithelial lesion or malignancy) during the same period were similarly reviewed. The follow-up Pap tests were classified into the various Bethesda 2001 diagnostic categories, and both groups were compared. The average follow-up duration in the study and control groups was 26.03 and 25.9 months, respectively. When all of the follow-up Pap tests in each group (study, n = 555; control, n = 356) were used for the comparisons, patients in the study group were significantly more likely to have an abnormal follow-up Pap test result than the control group patients (24.9% vs 7.6%, P < 0.0001); this was primarily attributable to the more frequent repeat interpretations of ASC-US in the former group (20.5% vs 5.1%, P < 0.0001). The HR HPV detection rates in the follow-up ASC-US cases were not significantly different between the study and control groups. There were no significant differences between both groups regarding the diagnostic frequencies of low-grade squamous intraepithelial lesion and atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (HGSIL). No examples of HGSIL or invasive cancer were identified in the follow-up of either group. All comparisons of statistical significance retained their significance when only 1 follow-up Pap test per patient, the most severe interpretation, was used. Our findings suggest that some significant differences exist between these 2 groups, most notably the comparatively increased frequency of repeat ASC-US interpretations in the study group. However, the extraordinary rarity of the most clinically significant interpretations of HGSIL and carcinoma in this setting can be confirmed because no such cases were identified during the follow-up of either group.
2001年的共识指南基本上将巴氏涂片检查结果为上皮内病变或恶性阴性的患者与结果为意义不明确的非典型鳞状细胞(ASC-US)且高危型人乳头瘤病毒(HR HPV)检测结果为阴性的患者的后续管理等同起来:在12个月后进行后续细胞学检查。由于这些指南在一定程度上得到广泛实施已有数年,我们试图确定在常规诊断的病例中,这两组患者的后续细胞学检查结果的全貌是否确实相同。回顾了连续6周内巴氏涂片检查结果为ASC-US的患者(n = 587)的临床和病理数据,这些患者进行了HR HPV检测(n = 497)且未检测到HR HPV(n = 300)(研究组)。随机选取同期巴氏涂片检查报告为阴性(上皮内病变或恶性阴性)的300例患者作为对照组进行类似回顾。将后续的巴氏涂片检查分类为各种2001年贝塞斯达诊断类别,并对两组进行比较。研究组和对照组的平均随访时间分别为26.03个月和25.9个月。当使用每组所有的后续巴氏涂片检查结果(研究组,n = 555;对照组,n = 356)进行比较时,研究组患者后续巴氏涂片检查结果异常的可能性显著高于对照组患者(24.9%对7.6%,P < 0.0001);这主要归因于前一组中ASC-US重复解读更为频繁(20.5%对5.1%,P < 0.0001)。研究组和对照组后续ASC-US病例中的HR HPV检测率无显著差异。两组在低级别鳞状上皮内病变和非典型鳞状细胞——不能排除高级别鳞状上皮内病变(HGSIL)的诊断频率方面无显著差异。两组的后续随访中均未发现HGSIL或浸润性癌的病例。当每位患者仅使用1次后续巴氏涂片检查结果(最严重的解读)时,所有具有统计学意义的比较仍具有显著性。我们的研究结果表明,这两组之间存在一些显著差异,最明显的是研究组中ASC-US重复解读的频率相对增加。然而,在这种情况下,HGSIL和癌的最具临床意义的解读极为罕见,这一点可以得到证实,因为两组的后续随访中均未发现此类病例。